Duloxetine

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Urinary Incontinence

Conditions

Urinary Incontinence

Trial Timeline

Nov 1, 2002 → Mar 1, 2005

NCT ID

NCT00475696

About Duloxetine

Duloxetine is a phase 2 stage product being developed by Eli Lilly for Urinary Incontinence. The current trial status is completed. This product is registered under clinical trial identifier NCT00475696. Target conditions include Urinary Incontinence.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01391221	Approved	UNKNOWN	Jul 1, 2011	Aug 1, 2013	Major Depression
NCT01363284	Pre-clinical	Completed	Jun 1, 2010	Aug 1, 2012	Diabetes
NCT01089621	Approved	Withdrawn	Mar 1, 2010	Aug 1, 2010	Fibromyalgia
NCT01051466	Approved	Completed	Jan 1, 2010	Mar 1, 2013	Major Depressive Disorder
NCT00989157	Phase 3	Completed	Sep 1, 2009	Nov 1, 2012	Bariatric Surgery
NCT01074151	Pre-clinical	Completed	Jul 1, 2009	Jul 26, 2021	Pregnancy
NCT00889369	Approved	UNKNOWN	May 1, 2009	Jun 1, 2012	Major Depressive Disorder
NCT01754493	Approved	Completed	Dec 1, 2008	Dec 1, 2014	Major Depression
NCT01028352	Pre-clinical	Completed	Oct 1, 2008	Oct 1, 2011	Breast Cancer
NCT00696774	Approved	Completed	Jun 1, 2008	Jul 1, 2009	Depressive Disorder, Major
NCT00532480	Approved	Completed	Sep 1, 2007	Apr 1, 2009	Major Depression
NCT00529789	Phase 2	Completed	Aug 1, 2007	Sep 1, 2008	Major Depressive Disorder
NCT00696293	Approved	Completed	May 1, 2007	Apr 1, 2010	Major Depressive Disorder
NCT00517985	Approved	Completed	Feb 1, 2007	Jun 1, 2008	Major Depressive Disorder
NCT00398632	Approved	Terminated	Nov 1, 2006	Apr 1, 2009	Depression
NCT00401258	Approved	Completed	Nov 1, 2006	Feb 1, 2008	Irritable Bowel Syndrome
NCT00438971	Approved	Completed	Aug 1, 2006	Jan 1, 2009	Panic Disorder
NCT00531895	Approved	Completed	Apr 1, 2006	Mar 1, 2007	Major Depression
NCT00322621	Approved	Completed	Apr 1, 2006	Oct 1, 2007	Diabetic Neuropathies
NCT01035073	Approved	Completed	Apr 1, 2006	May 1, 2009	Major Depressive Disorder

Competing Products

20 competing products in Urinary Incontinence

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + placebo	Eli Lilly	Phase 2	52
Enfortumab vedotin	Astellas Pharma	Phase 1	33
solifenacin succinate + tamsulosin + placebo	Astellas Pharma	Approved	85
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosin	Astellas Pharma	Phase 2	52
Solifenacin	Astellas Pharma	Approved	85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to Tolterodine	Astellas Pharma	Phase 3	77
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)	Astellas Pharma	Approved	85
solifenacin succinate	Astellas Pharma	Phase 3	77
Solifenacin	Astellas Pharma	Pre-clinical	23
Solifenacin	Astellas Pharma	Pre-clinical	23
Tamuslosin	Astellas Pharma	Phase 3	77
Tamsulosin + Solifenacin	Astellas Pharma	Approved	85
Alpha blocker + placebo + solifenacin	Astellas Pharma	Approved	85
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placebo	Astellas Pharma	Phase 3	77
solifenacin succinate + tolterodine	Astellas Pharma	Phase 3	77
Tamusulosin	Astellas Pharma	Phase 3	77
Solifenacin	Astellas Pharma	Pre-clinical	23
Solifenacin succinate + Tolterodine	Astellas Pharma	Phase 3	77
Solifenacin succinate + Placebo	Astellas Pharma	Phase 3	77
Vesicare	Astellas Pharma	Pre-clinical	23

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved